Zeus Hygia Lifesciences enters North American nutraceutical market with BioSOLVE Technology
In response to the increasing number of science-backed ingredient launches coupled with consumer demand for non-pill supplements, Hyderabad-based Zeus Hygia Lifesciences has launched its exclusive patent-pending BioSOLVE Technology.
“The fact that more ingredients are being introduced into the marketplace for novel product development is attractive, yet a fair number of those exhibit poor solubility and bioavailability, and eventually the end user, being consumers, get minimal therapeutic benefits,” said Arunkanth Krishnakumar, Zeus Hygia co-founder and director of business development and strategies.
Zeus BioSOLVE Technology offers higher bioavailability for active ingredients by utilizing food-grade encapsulating excipients. “Our novel platform for improving solubility and bioavailability of poorly soluble actives, offers not only a new technology, but one of the most advanced and scalable platform technologies to increase bio-efficacy, potency and bioavailability,” said Krishnakumar.
The goal of BioSOLVE Technology is to encapsulate water-insoluble actives in a food-grade water soluble matrix using novel phase coacervation techniques. This technology helps to deliver actives in situ at a submicron range with increased water solubility and maximum efficacy. The carrier used in the encapsulation process is GRAS and widely used in food applications across the globe.
The hydrophilic carrier system used in Zeus BioSOLVE Technology has unique emulsifying properties and forms adequate hydrophilic/lipophilic balance around the bioactive molecules, leading to enhanced absorption by the gut wall. The improved bioavailability is due to several factors, including an increase in water solubility with better dissolution properties, as well as finer and uniform particles with larger surface area.
Further, a benefit of Zeus BioSOLVE Technology is that manufacturers can use less of an ingredient for the same deliverable impact, i.e., users can consume less than the normal dose with uncompromised bioavailability.